Telix Pharmaceuticals (TLX) Status update summary

Portfolio and Clinical Pipeline Overview

• Neuro-oncology portfolio targets gliomas and glioblastoma, with late-stage and next-generation assets focused on LAT1 and LAT2 transporters.

• Lead candidate TLX101 (iodine-based) is in a pivotal phase III trial (IPAX BrIGHT) for recurrent glioblastoma; TLX102 (astatine-based) is in earlier development.

• TLX101-Tx and TLX102-Tx are key therapeutic candidates, with TLX101-Px (Pixclara/Pixlumi) as a first-in-class imaging agent under regulatory review in the US and Europe.

• Portfolio includes both beta and alpha therapies, with in-house manufacturing and distribution capabilities.

• Theranostic approach combines imaging and therapy for precise diagnosis and targeted treatment.

Clinical Trial Updates and Results

• TLX101-Tx has shown favorable safety and efficacy in malignant glioma trials, with no dose-limiting toxicities observed.

• Phase I/II studies (IPAX-1, IPAX-Linz) showed TLX101 is well-tolerated with encouraging overall survival (12–13 months from treatment, 23–32 months from diagnosis).

• Phase 3 IPAX BrIGHT trial is dosing recurrent glioblastoma patients globally, with overall survival as the primary endpoint; first cohort fully enrolled in Australia and Europe.

• Regulatory approvals for IPAX BrIGHT obtained in seven European countries; US expansion pending FDA clearance.

• Phase 1 IPAX-2 trial for newly diagnosed GBM patients has completed enrollment, showing good tolerability.

Imaging Innovation and Diagnostic Advances

• TLX101-Px (Pixclara) combined with MRI achieves 93% sensitivity and 94% specificity for glioma detection.

• Amino acid PET tracers like TLX101-Px improve diagnostic accuracy over standard MRI, aiding clinical decision-making.

• MRI is standard for glioma imaging but has limitations; up to 40% of scans are equivocal for disease progression.

• Pixclara is under FDA review with a target approval date in mid-September.

• Imaging can differentiate between treatment-related changes and true disease progression, supporting better patient management.